MCID: ESP027
MIFTS: 35

Esophagus Squamous Cell Carcinoma

Categories: Cancer diseases, Gastrointestinal diseases

Aliases & Classifications for Esophagus Squamous Cell Carcinoma

MalaCards integrated aliases for Esophagus Squamous Cell Carcinoma:

Name: Esophagus Squamous Cell Carcinoma 12 15
Squamous Cell Carcinoma of Esophagus 74
Scc of Esophagus 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3748
MeSH 45 C562729
NCIt 51 C4024
UMLS 74 C0279626

Summaries for Esophagus Squamous Cell Carcinoma

Disease Ontology : 12 An esophageal carcinoma that derives from epithelial squamous cells located in the esophagus.

MalaCards based summary : Esophagus Squamous Cell Carcinoma, also known as squamous cell carcinoma of esophagus, is related to esophageal cancer and squamous cell carcinoma. An important gene associated with Esophagus Squamous Cell Carcinoma is MIR296 (MicroRNA 296), and among its related pathways/superpathways is LncRNA-mediated mechanisms of therapeutic resistance. The drugs Cisplatin and Paclitaxel have been mentioned in the context of this disorder. Affiliated tissues include lung, lymph node and liver.

Related Diseases for Esophagus Squamous Cell Carcinoma

Diseases related to Esophagus Squamous Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 33)
# Related Disease Score Top Affiliating Genes
1 esophageal cancer 11.4
2 squamous cell carcinoma 10.6
3 functionless pituitary adenoma 10.0 HOTAIR MEG3
4 pituitary adenoma 10.0 HOTAIR MEG3
5 ovarian epithelial cancer 10.0 HOTAIR MEG3
6 tongue squamous cell carcinoma 10.0 AFAP1-AS1 MEG3
7 gastric cardia adenocarcinoma 10.0 HOTAIR MEG3
8 colorectal adenocarcinoma 10.0
9 adenocarcinoma 10.0
10 lymphopenia 10.0
11 pancreatic ductal adenocarcinoma 10.0 AFAP1-AS1 HOTAIR
12 gastrointestinal system cancer 9.9 BANCR HOTAIR
13 kidney cancer 9.8 HOTAIR MEG3
14 oral squamous cell carcinoma 9.8 HOTAIR MEG3 MIR296
15 cerebrovascular disease 9.8 HOTAIR MEG3
16 glioma 9.8 HOTAIR MEG3 MIR296
17 gallbladder cancer 9.8 AFAP1-AS1 HOTAIR MEG3
18 adamantinoma of long bones 9.7 AFAP1-AS1 HOTAIR MEG3
19 thyroid cancer, nonmedullary, 1 9.7 BANCR HOTAIR MEG3
20 osteogenic sarcoma 9.7 BANCR HOTAIR MEG3
21 nasopharyngeal carcinoma 9.7 AFAP1-AS1 HOTAIR MEG3
22 glioblastoma 9.7 HOTAIR MEG3 MIR296
23 osteoarthritis 9.7 HOTAIR MEG3
24 bladder cancer 9.7 BANCR HOTAIR MEG3
25 retinoblastoma 9.7 BANCR HOTAIR MEG3
26 lung cancer susceptibility 3 9.7 AFAP1-AS1 HOTAIR MEG3
27 melanoma 9.7 BANCR HOTAIR MEG3
28 bladder urothelial carcinoma 9.6 HOTAIR MEG3
29 ovarian cancer 9.5 AFAP1-AS1 HOTAIR MEG3 MIR296
30 gastric cancer 9.5 AFAP1-AS1 BANCR HOTAIR MEG3
31 lung cancer 9.4 AFAP1-AS1 BANCR HOTAIR MEG3
32 hepatocellular carcinoma 9.4 AFAP1-AS1 BANCR HOTAIR MEG3
33 colorectal cancer 9.2 AFAP1-AS1 BANCR HOTAIR MEG3 MIR296

Graphical network of the top 20 diseases related to Esophagus Squamous Cell Carcinoma:



Diseases related to Esophagus Squamous Cell Carcinoma

Symptoms & Phenotypes for Esophagus Squamous Cell Carcinoma

Drugs & Therapeutics for Esophagus Squamous Cell Carcinoma

Drugs for Esophagus Squamous Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 172)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 2767 441203 84093
2
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 33069-62-4 36314
3
Aspirin Approved, Vet_approved Phase 3,Early Phase 1 50-78-2 2244
4
Irinotecan Approved, Investigational Phase 3,Phase 2,Phase 1 100286-90-6, 97682-44-5 60838
5
Fluorouracil Approved Phase 3,Phase 2,Phase 1,Not Applicable 51-21-8 3385
6
Capecitabine Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 154361-50-9 60953
7
Cetuximab Approved Phase 2, Phase 3,Phase 3,Phase 1 205923-56-4 56842117 2333
8
leucovorin Approved Phase 2, Phase 3,Phase 3,Phase 1 58-05-9 143 6006
9
Oxaliplatin Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 61825-94-3 43805 6857599 5310940 9887054
10
Docetaxel Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 114977-28-5 148124
11
Carboplatin Approved Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 41575-94-4 10339178 38904 498142
12
Levoleucovorin Approved, Investigational Phase 2, Phase 3,Phase 1 68538-85-2
13
Gefitinib Approved, Investigational Phase 3,Phase 2,Phase 1 184475-35-2 123631
14
Nedaplatin Approved, Investigational Phase 3,Phase 2,Phase 1 95734-82-0
15
Panitumumab Approved, Investigational Phase 3,Phase 2 339177-26-3 50070211
16
Cobalt Approved, Experimental Phase 3 7440-48-4 104729
17
Vinorelbine Approved, Investigational Phase 3,Phase 2 71486-22-1 44424639 60780
18
Ipilimumab Approved Phase 3,Phase 2 477202-00-9
19
nivolumab Approved Phase 3,Phase 1,Phase 2 946414-94-4
20
Megestrol acetate Approved, Investigational, Vet_approved Phase 3 595-33-5 11683
21
Trioxsalen Approved Phase 3 3902-71-4 5585
22
Pembrolizumab Approved Phase 3,Phase 2,Phase 1 1374853-91-4
23
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3,Phase 1 59-30-3 6037
24
Nimotuzumab Investigational Phase 2, Phase 3,Phase 3,Phase 1 780758-10-3, 828933-61-3
25
Caffeic acid Experimental, Investigational Phase 3 331-39-5, 501-16-6 1549111
26 Antimitotic Agents Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
27 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
28 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
29
s 1 (combination) Phase 3,Phase 2,Phase 1
30 Antineoplastic Agents, Immunological Phase 2, Phase 3,Phase 3,Phase 1
31 Analgesics Phase 3,Phase 2,Early Phase 1
32 Antipyretics Phase 3,Early Phase 1
33 Peripheral Nervous System Agents Phase 3,Phase 2,Early Phase 1
34 Anti-Inflammatory Agents Phase 3,Phase 2,Early Phase 1
35 Tea Phase 3
36 Fibrinolytic Agents Phase 3,Early Phase 1
37 Antirheumatic Agents Phase 3,Phase 2,Early Phase 1
38 Cyclooxygenase Inhibitors Phase 3,Phase 2,Early Phase 1
39 Anti-Inflammatory Agents, Non-Steroidal Phase 3,Phase 2,Early Phase 1
40 Analgesics, Non-Narcotic Phase 3,Phase 2,Early Phase 1
41 Platelet Aggregation Inhibitors Phase 3,Phase 2,Early Phase 1
42 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
43 topoisomerase I inhibitors Phase 3,Phase 2,Phase 1
44 Antimetabolites Phase 3,Phase 2,Phase 1,Not Applicable
45 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Not Applicable
46 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1,Not Applicable
47 Immunologic Factors Phase 3,Phase 2,Phase 1,Not Applicable
48 Vitamin B9 Phase 2, Phase 3,Phase 1
49 Vitamin B Complex Phase 2, Phase 3,Phase 1
50 Folate Phase 2, Phase 3,Phase 1

Interventional clinical trials:

(show top 50) (show all 306)
# Name Status NCT ID Phase Drugs
1 Cisplatin Combined With S-1 or Paclitaxel as First-line Treatment for Metastatic Esophageal Squamous Cell Carcinoma Unknown status NCT02677597 Phase 3 Cisplatin Combined With S-1;Cisplatin Combined With Paclitaxel
2 Chemoradiation With or Without Nimotuzumab in Treating Esophageal Cancer Patients Who Suffer With Recurrence in Regional Lymph Nodes After Esophagectomy Unknown status NCT01402180 Phase 2, Phase 3 chemotherapy;chemotherapy
3 Chemoprevention of Esophageal Squamous Cell Carcinoma (ESCC) With Aspirin and Tea Polyphenols Unknown status NCT01496521 Phase 3 Aspirin
4 Is ENI Necessary For Patients With Thoracic Esophageal Cancer After Esophagectomy And With Pathological Stage Of T1-2,N+,M0 Unknown status NCT01398449 Phase 3
5 Irinotecan Plus S1 Versus S1 in Patients With Previously Treated Advanced Esophageal Cancer: ESWN 01 Trial Unknown status NCT02319187 Phase 3 S1;S-1;irinotecan
6 Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Esophagus Unknown status NCT00002884 Phase 3 chemotherapy;cisplatin;fluorouracil
7 Cisplatin, Capecitabine, and Radiation Therapy With or Without Cetuximab in Treating Patients With Esophageal Cancer Unknown status NCT00509561 Phase 2, Phase 3 capecitabine;cisplatin
8 A Phase III Study of Comparing Paclitaxel Plus 5-Fluorouracil Versus Cisplatin Plus 5-Fluorouracil in Chemoradiotherapy for Locally Advanced Esophageal Carcinoma Completed NCT01591135 Phase 3 Paclitaxel plus 5-fluorouracil;Cisplatin plus 5-fluorouracil
9 Surgery With or Without Chemotherapy in Treating Patients With Stage II or Stage III Cancer of the Esophagus Completed NCT00002897 Phase 3 cisplatin;fluorouracil
10 Surgery With or Without Radiation Therapy and Chemotherapy in Treating Patients With Esophageal Cancer Completed NCT00047112 Phase 3 cisplatin;fluorouracil
11 Surgery or Chemoradiation for Esophageal Cancer Completed NCT01032967 Phase 3
12 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Cancer of the Esophagus Completed NCT00002631 Phase 3 chemotherapy;cisplatin;fluorouracil
13 Surgery With or Without Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Esophagus Completed NCT00003118 Phase 3 cisplatin;fluorouracil
14 Radiation Therapy + Combination Chemotherapy as 1st-Line Therapy for Patients With Inoperable Esophageal Cancer Completed NCT00861094 Phase 2, Phase 3 cisplatin;5-FU;oxaliplatin;Folinic Acid
15 Gefitinib in Treating Patients With Esophageal Cancer That is Progressing After Chemotherapy Completed NCT01243398 Phase 3
16 Radiation Therapy and Chemotherapy, With or Without Cetuximab, Followed by Surgery in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed by Surgery Completed NCT01107639 Phase 3 cisplatin;docetaxel
17 Postoperative Concurrent Chemoradiotherapy Versus Radiotherapy Alone for Patients With Locoregionally Advanced Esophageal Squamous Cell Carcinoma Recruiting NCT03600831 Phase 2, Phase 3 Docetaxel plus cisplatin
18 Toripalimab or Placebo With Paclitaxel and Cisplatin in Esophageal Squamous Cell Carcinoma Recruiting NCT03829969 Phase 3
19 Nimotuzumab in Combined With Paclitaxel and Cisplatin for Treatment of Metastatic Esophageal Squamous Cell Carcinoma Recruiting NCT02611700 Phase 3 Nimotuzumab;Paclitaxel;Cisplatin;Placebo
20 A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Patients With Advanced Esophageal Squamous Cell Carcinoma Recruiting NCT03783442 Phase 3 Platinum (cisplatin or oxaliplatin) + Fluorouracil (5-FU);Platinum (cisplatin or oxaliplatin) + capecitabine;Platinum (cisplatin or oxaliplatin) + paclitaxel
21 A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Esophageal Squamous Cell Carcinoma Recruiting NCT03430843 Phase 3 BGB-A317;Paclitaxel, or Docetaxel, or Irinotecan
22 A Comparison of Paclitaxel-based Three Regimens Concurrent With Radiotherapy for Patients With Local Advanced Esophageal Cancer Recruiting NCT02459457 Phase 3 Paclitaxel and Cisplatin;Paclitaxel and Fluorouracil;Paclitaxel and Carboplatin
23 A Clinical Trial Comparing HLX10 With Placebo Combined With Chemotherapy (Cisplatin + 5-fu) in the First-line Treatment of Locally Advanced/Metastatic Esophageal Squamous Cell Carcinoma (ESCC) Recruiting NCT03958890 Phase 3 HLX10 100 mg in 10 ml Injection;Placebos
24 A Phase III Trail of Adjuvant Chemoradiotherapy Versus Adjuvant Radiotherapy in Esophageal Squamous Cell Carcinoma Recruiting NCT02570893 Phase 3 Paclitaxel and carboplatin
25 Neoadjuvant Chemotherapy Versus Surgery Alone for Esophageal Squamous Cell Carcinoma Recruiting NCT02395705 Phase 3 cisplatin and paclitaxel
26 A Phase III Study of Nimotuzumab Plus Concurrent Chemoradiotherapy in Loco-regional Esophageal Squamous Cell Carcinoma Recruiting NCT02409186 Phase 3 Nimotuzumab;chemoradiotherapy Paclitaxel;chemoradiotherapy Cisplatin
27 Adjuvant Chemotherapy With Paclitaxel and Cisplatin in Lymph Node-Positive Adjuvant Chemotherapy in the Treatment of the Lymph Node Positive Thoracic Esophageal Squamous Cell Carcinoma Recruiting NCT02461043 Phase 3 paclitaxel; cisplatin
28 Improve the Treatment of Thoracic Esophageal Cancer Recruiting NCT01137123 Phase 3 adjuvant chemotherapy
29 Comparing Paclitaxel/Cisplatin and Cisplatin/5-fluorouracil in Neo-CRT for ESCC Recruiting NCT03623737 Phase 2, Phase 3 neoadjuvant chemoradiation
30 Different Cycles of Cisplatin-5-fluorouracil for the Chemoradiotherapy of Esophageal Squamous Cancer Recruiting NCT02607540 Phase 3
31 Comparing 61.2 Gy Radiotherapy Dose Versus 50.4 Gy Radiotherapy Dose for Locally Advanced Esophageal Carcinoma Recruiting NCT03790553 Phase 3
32 Chemoradiotherapy of Capecitabine With or Without Oxaliplatin Versus Cisplatin-5-FU for Esophageal Squamous Cancer Recruiting NCT02025036 Phase 3 Capecitabine(Aibin);Oxaliplatin(Aiheng)
33 The Role of Different Cycles of Chemotherapy(Capecitabine-oxaliplatin) in Esophageal Chemoradiotherapy Recruiting NCT02604615 Phase 3 Capecitabine(Aibin);Oxaliplatin(Aiheng)
34 Chemoradiotherapy With or Without Enteral Nutrition for Locally Advanced Thoracic Esophageal Carcinoma Recruiting NCT02399306 Phase 3 Enteral nutrition
35 Adjuvant Therapies or Surgery Alone for High Risk pN0 Esophageal Cancer Recruiting NCT02891083 Phase 3 Adjuvant chemotherapy (Paclitaxel and Cisplatin)
36 Study of Docetaxel or Vinorelbine Plus Cisplatin in Neoadjuvant Chemoradiotherapy for Esophageal Cancer Recruiting NCT02465736 Phase 3 Docetaxel;Cisplatin;Vinorelbine;Cisplatin
37 A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin Recruiting NCT03143153 Phase 3 Cisplatin;Fluorouracil
38 Different Cycles of Capecitabine Usage in Esophageal Cancer Concurrent Chemoradiotherapy Recruiting NCT02603159 Phase 3 Capecitabine(Aibin)
39 Effect of Megestrol Acetate on the Quality of Life of Patients With Esophageal Carcinoma Recruiting NCT02644408 Phase 3 Megestrol(Yining)
40 S-1 Concurrent With Radiotherapy Versus Radiotherapy for Elderly Patients With Esophageal Cancer Recruiting NCT02813967 Phase 3 S-1
41 Robot-assisted Esophagectomy Versus Conventional Thoracoscopic Esophagectomy Recruiting NCT03094351 Phase 3
42 Simultaneous Modulated Accelerated Boost Versus Standard Dose Radiotherapy in Esophageal Cancer Recruiting NCT02556762 Phase 3 PF
43 Salvage Chemoradiation Therapy for Recurrence After Radical Surgery or Palliative Surgery in Esophageal Cancer Patients Recruiting NCT03731442 Phase 3 Paclitaxel;Platinum;PEG-rhG-CSF
44 Clinical Study of Time Optimizing of Endoscopic Photodynamic Therapy on Esophageal and/or Gastric Cardiac Cancer Recruiting NCT02628665 Phase 3 photosensitizer(photofrin)
45 Efficacy of Intensity Modulated Radiation Therapy After Surgery in Early Stage of Esophageal Carcinoma; Active, not recruiting NCT01745107 Phase 3
46 Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)-China Extension Study Active, not recruiting NCT03933449 Phase 3 paclitaxel;docetaxel;irinotecan
47 Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181) Active, not recruiting NCT02564263 Phase 3 paclitaxel;docetaxel;irinotecan
48 Phase III Study of Neo-adjuvant Chemoradiotherapy Followed by Surgery for Squamous Cell Esophageal Cancer Active, not recruiting NCT01216527 Phase 3
49 Study of SHR-1210 Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal Cancer Active, not recruiting NCT03099382 Phase 3 Docetaxel;Irinotecan
50 Paclitaxel, Cisplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Locally Advanced Esophageal Cancer Active, not recruiting NCT00655876 Phase 3 cetuximab;cisplatin;paclitaxel

Search NIH Clinical Center for Esophagus Squamous Cell Carcinoma

Genetic Tests for Esophagus Squamous Cell Carcinoma

Anatomical Context for Esophagus Squamous Cell Carcinoma

MalaCards organs/tissues related to Esophagus Squamous Cell Carcinoma:

42
Lung, Lymph Node, Liver, Breast, Endothelial, Pituitary, T Cells

The Foundational Model of Anatomy Ontology organs/tissues related to Esophagus Squamous Cell Carcinoma:

20
The Esophagus

Publications for Esophagus Squamous Cell Carcinoma

Articles related to Esophagus Squamous Cell Carcinoma:

(show top 50) (show all 58)
# Title Authors Year
1
Long noncoding RNA HAND2-AS1 inhibits cancer cell proliferation, migration, and invasion in esophagus squamous cell carcinoma by regulating microRNA-21. ( 30520131 )
2019
2
REV7 confers radioresistance of esophagus squamous cell carcinoma by recruiting PRDX2. ( 30657231 )
2019
3
Identifying the differentially expressed microRNAs in esophagus squamous cell carcinoma of Kazakh patients in Xinjiang. ( 30854040 )
2019
4
Targeting Orai1-mediated store-operated calcium entry by RP4010 for anti-tumor activity in esophagus squamous cell carcinoma. ( 29908962 )
2018
5
Clinic implication of MUC1 O-glycosylation and C1GALT1 in esophagus squamous cell carcinoma. ( 30076562 )
2018
6
Comparison of the effect of postoperative radiotherapy with surgery alone for esophagus squamous cell carcinoma patients: A meta-analysis. ( 30461614 )
2018
7
Considering the downregulation of Tpm1.6 and Tpm1.7 in squamous cell carcinoma of esophagus as a potent biomarker. ( 30259780 )
2018
8
The impact of pathological complete response after neoadjuvant chemoradiotherapy in locally advanced squamous cell carcinoma of esophagus. ( 29066057 )
2018
9
Endoscopic diagnosis and management of early squamous cell carcinoma of esophagus. ( 28815064 )
2017
10
Pretreatment lymphopenia is an easily detectable predictive and prognostic marker in patients with metastatic esophagus squamous cell carcinoma receiving first-line chemotherapy. ( 26814381 )
2016
11
Kaempferol inhibits cell proliferation and glycolysis in esophagus squamous cell carcinoma via targeting EGFR signaling pathway. ( 26831667 )
2016
12
Amplification and overexpression of CTTN and CCND1 at chromosome 11q13 in Esophagus squamous cell carcinoma (ESCC) of North Eastern Chinese Population. ( 27877079 )
2016
13
Genotypes of CYP1A1, SULT1A1 and SULT1A2 and risk of squamous cell carcinoma of esophagus: outcome of a case-control study from Kashmir, India. ( 26455829 )
2016
14
MiR-205 functions as a tumor suppressor in adenocarcinoma and an oncogene in squamous cell carcinoma of esophagus. ( 26711784 )
2016
15
Multiple Meningocerebral Metastasis and Extensive Skull Metastasis from Squamous Cell Carcinoma of Esophagus: A Case Report and Review of Literature. ( 27867927 )
2016
16
Outcomes of patients with squamous cell carcinoma of esophagus who did not receive surgical resection after neoadjuvant radiochemotherapy. ( 25908044 )
2015
17
Diagnostic and prognostic potential of miR-21, miR-29c, miR-148 and miR-203 in adenocarcinoma and squamous cell carcinoma of esophagus. ( 25928282 )
2015
18
Leu432Val Polymorphism of CYP1B1 is Not Associated with Squamous Cell Carcinoma of Esophagus--a Case-Control Study from Kashmir, India. ( 26225675 )
2015
19
Perioperative versus Preoperative Chemotherapy with Surgery in Patients with Resectable Squamous Cell Carcinoma of Esophagus: A Phase III Randomized Trial. ( 26287319 )
2015
20
Prognostic value of tumor-infiltrating mast cells in outcome of patients with esophagus squamous cell carcinoma. ( 24091743 )
2014
21
Prognostic value of metastatic lymph nodal ratio in squamous cell carcinoma of esophagus: A three-step extrapolative study. ( 25422807 )
2014
22
Human papillomavirus types 16 and 18 in esophagus squamous cell carcinoma: a meta-analysis. ( 23916383 )
2013
23
A phase II study of oxaliplatin in combination with leucovorin and fluorouracil as first-line chemotherapy in patients with metastatic squamous cell carcinoma of esophagus. ( 23370661 )
2013
24
Adverse effects of preserved vegetables on squamous cell carcinoma of esophagus and precancer lesions in a high risk area. ( 23621214 )
2013
25
Role of postoperative radiotherapy for microscopic margin involvement in the squamous cell carcinoma of esophagus. ( 24155679 )
2013
26
Dermatan sulfate is involved in the tumorigenic properties of esophagus squamous cell carcinoma. ( 22350411 )
2012
27
Prediagnostic smoking and postoperative survival in lymph node-negative esophagus squamous cell carcinoma patients. ( 22913634 )
2012
28
Retrospective study of gemcitabine based chemotherapy for unresectable or recurrent esophagus squamous cell carcinoma refractory to first line chemotherapy. ( 23098537 )
2012
29
A phase I dose escalation study of Nimotuzumab in combination with concurrent chemoradiation for patients with locally advanced squamous cell carcinoma of esophagus. ( 21901403 )
2012
30
Parotid gland metastasis from squamous cell carcinoma of esophagus detected by FDG PET/CT. ( 22955076 )
2012
31
Downregulation of tropomyosin-1 in squamous cell carcinoma of esophagus, the role of Ras signaling and methylation. ( 22965424 )
2012
32
Use of pretreatment metabolic tumor volumes on PET-CT to predict the survival of patients with squamous cell carcinoma of esophagus treated by curative surgery. ( 22993379 )
2012
33
Analysis of the RUNX3 gene methylation in serum DNA from esophagus squamous cell carcinoma, gastric and colorectal adenocarcinoma patients. ( 22234069 )
2011
34
MDM2 is overexpressed and regulated by the eukaryotic translation initiation factor 4E (eIF4E) in human squamous cell carcinoma of esophagus. ( 21080085 )
2011
35
Mimicry of physiological urinary FDG excretion: squamous cell carcinoma of esophagus metastasizing to psoas muscle. ( 21157206 )
2011
36
Role of preoperative chemotherapy in squamous cell carcinoma of esophagus in kashmir, a cancer belt - a pilot study. ( 21545214 )
2011
37
Squamous cell carcinoma of esophagus in a 15-year-old boy. ( 20975784 )
2010
38
Positive impact of radiation dose on disease free survival and locoregional control in postoperative radiotherapy for squamous cell carcinoma of esophagus. ( 19021683 )
2009
39
Numb chin syndrome as a manifestation of metastatic squamous cell carcinoma of esophagus. ( 19293491 )
2009
40
Reduced axin protein expression is associated with a poor prognosis in patients with squamous cell carcinoma of esophagus. ( 19582507 )
2009
41
Evaluation of visualization of squamous cell carcinoma of esophagus and pharynx using an autofluorescence imaging videoendoscope system. ( 19780882 )
2009
42
Concurrent chemoradiotherapy or endoscopic stenting for advanced squamous cell carcinoma of esophagus: a case-control study. ( 18057993 )
2008
43
[Transforming growth factor beta1 regulation of epithelial-mesenchymal transition in esophagus squamous cell carcinoma]. ( 19094466 )
2008
44
Choriocarcinoma - a rare association with squamous cell carcinoma of esophagus. ( 16567899 )
2006
45
Human papillomavirus in squamous cell carcinoma of esophagus in a high-risk population. ( 15754405 )
2005
46
Squamous cell carcinoma of esophagus masquerading as solitary thyroid nodule. ( 16391440 )
2005
47
Umbilical metastasis with squamous cell carcinoma of esophagus. ( 15333983 )
2004
48
Colonic metastasis from squamous cell carcinoma of esophagus. ( 12416763 )
2002
49
Gene expression profile changes in initiation and progression of squamous cell carcinoma of esophagus. ( 11169949 )
2001
50
Efficacy of computed axial tomography in the evaluation of the involvement of the respiratory tract in patients with squamous cell carcinoma of esophagus. ( 10631912 )
1999

Variations for Esophagus Squamous Cell Carcinoma

Expression for Esophagus Squamous Cell Carcinoma

Search GEO for disease gene expression data for Esophagus Squamous Cell Carcinoma.

Pathways for Esophagus Squamous Cell Carcinoma

Pathways related to Esophagus Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 9.7 HOTAIR MEG3

GO Terms for Esophagus Squamous Cell Carcinoma

Sources for Esophagus Squamous Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....